Aimmune Therapeutics Stock Price, News & Analysis (NASDAQ:AIMT)

$37.20 -1.04 (-2.72 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$37.20
Today's Range$36.99 - $38.66
52-Week Range$15.97 - $40.65
Volume262,260 shs
Average Volume437,329 shs
Market Capitalization$1.89 billion
P/E Ratio-15.90
Dividend YieldN/A
BetaN/A

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics logoAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AIMT
CUSIPN/A
Phone+1-650-6145220

Debt

Debt-to-Equity RatioN/A
Current Ratio10.30%
Quick Ratio10.30%

Price-To-Earnings

Trailing P/E Ratio-15.8974358974359
Forward P/E Ratio-14.82
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.73 per share
Price / Book6.49

Profitability

Trailing EPS($2.34)
Net Income$-80,820,000.00
Net MarginsN/A
Return on Equity-46.18%
Return on Assets-43.28%

Miscellaneous

Employees69
Outstanding Shares50,860,000

Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.09. View Aimmune Therapeutics' Earnings History.

Where is Aimmune Therapeutics' stock going? Where will Aimmune Therapeutics' stock price be in 2018?

7 brokers have issued twelve-month target prices for Aimmune Therapeutics' stock. Their forecasts range from $45.00 to $75.00. On average, they expect Aimmune Therapeutics' stock price to reach $60.57 in the next year. View Analyst Ratings for Aimmune Therapeutics.

What are Wall Street analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (1/31/2018)
  • 2. Piper Jaffray Companies analysts commented, "Today Aimmune reported 4Q16 financial results, ending the quarter with $249M in cash. We think this cash funds the company through at least YE18. By this time, we should have results from its Phase III PALISADE program in peanut allergy and we see compelling efficacy as well as safety here as the key value-creating event for AIMT shares around YE17/early '18. By YE18, we also expect a BLA filing submitted for use in kids and teens. Based on guidance of BLA timing, and assuming the full year for BLA prep, filing and review (despite the BTD status granted to AR101), we're modestly adjusting first US peds/teens sales from 2019 to 2020, resulting in a new PT of $38. Despite this change, we continue to recommend AIMT in advance of 12-month clinical progress including, importantly, PALISADE up-dosing completion around mid'17 which we see as potentially reducing clinical risk for the program." (3/15/2017)

Who are some of Aimmune Therapeutics' key competitors?

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the folowing people:

  • Mark D. McDade, Independent Chairman of the Board (Age 61)
  • Stephen G. Dilly M.D. Ph.D., President, Chief Executive Officer, Director (Age 57)
  • Eric H. Bjerkholt, Chief Financial Officer (Age 57)
  • Jeffrey H. Knapp, Chief Operating Officer (Age 51)
  • Susan E. Barrowcliffe, Senior Vice President, General Manager of Europe (Age 59)
  • Mary M. Rozenman, Senior Vice President - Strategy and Corporate Development (Age 36)
  • Douglas T. Sheehy J.D., General Counsel, Secretary (Age 50)
  • Sue Barrowcliffe, General Manager of Europe
  • Daniel C. Adelman M.D., Chief Medical Officer (Age 56)
  • Greg Behar, Independent Director (Age 47)

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO.

Who owns Aimmune Therapeutics stock?

Aimmune Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.39%), FMR LLC (5.05%), FMR LLC (5.05%), Aisling Capital LLC (4.40%), Eagle Asset Management Inc. (3.92%) and Carillon Tower Advisers Inc. (3.06%). Company insiders that own Aimmune Therapeutics stock include Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Foresite Capital Fund Ii, LP, Longitude Capital Partners Ii,, Mary M Rozenman, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.

Who sold Aimmune Therapeutics stock? Who is selling Aimmune Therapeutics stock?

Aimmune Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC, Citadel Advisors LLC, UBS Asset Management Americas Inc., Eagle Asset Management Inc., Goldman Sachs Group Inc., Palo Alto Investors LLC, Vivo Capital LLC and C WorldWide Group Holding A S. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, Douglas T Sheehy, Mary M Rozenman, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Insider Buying and Selling for Aimmune Therapeutics.

Who bought Aimmune Therapeutics stock? Who is buying Aimmune Therapeutics stock?

Aimmune Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Alliancebernstein L.P., Franklin Resources Inc., Highland Capital Management LP, Hamilton Lane Advisors LLC, Schwab Charles Investment Management Inc., Glenmede Trust Co. NA and MetLife Investment Advisors LLC. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Eric Bjerkholt and Longitude Capital Partners Ii,. View Insider Buying and Selling for Aimmune Therapeutics.

How do I buy Aimmune Therapeutics stock?

Shares of Aimmune Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of Aimmune Therapeutics stock can currently be purchased for approximately $37.20.

How big of a company is Aimmune Therapeutics?

Aimmune Therapeutics has a market capitalization of $1.89 billion. The biotechnology company earns $-80,820,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Aimmune Therapeutics employs 69 workers across the globe.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 Marina Blvd Ste 300, BRISBANE, CA 94005-1884, United States. The biotechnology company can be reached via phone at +1-650-6145220 or via email at [email protected]


MarketBeat Community Rating for Aimmune Therapeutics (AIMT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aimmune Therapeutics (NASDAQ:AIMT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $60.57$59.00$53.25$36.67
Price Target Upside: 60.07% upside51.28% upside52.36% upside91.77% upside

Aimmune Therapeutics (NASDAQ:AIMT) Consensus Price Target History

Price Target History for Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics (NASDAQ:AIMT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018WedbushReiterated RatingOutperformLowView Rating Details
2/7/2018Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$55.00HighView Rating Details
1/31/2018Roth CapitalBoost Price TargetBuy$60.00 -> $75.00MediumView Rating Details
1/11/2018Credit Suisse GroupSet Price TargetBuy$45.00LowView Rating Details
12/20/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$64.00MediumView Rating Details
12/12/2017Cantor FitzgeraldInitiated CoverageOverweight$55.00HighView Rating Details
12/5/2017Piper Jaffray CompaniesBoost Price TargetOverweight$38.00 -> $60.00LowView Rating Details
9/26/2016JMP SecuritiesInitiated CoverageOutperform$30.00N/AView Rating Details
5/16/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Aimmune Therapeutics (NASDAQ:AIMT) Earnings History and Estimates Chart

Earnings by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics (NASDAQ AIMT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.72)($0.63)ViewN/AView Earnings Details
8/8/2017Q2($0.64)($0.65)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.57)($0.52)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.47)($0.55)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.45)($0.53)ViewN/AView Earnings Details
8/10/2016Q216($0.42)($0.43)ViewN/AView Earnings Details
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details
11/4/2015Q3 2015($0.24)($0.36)ViewN/AView Earnings Details
8/31/2015Q2 2015($1.60)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aimmune Therapeutics (NASDAQ:AIMT) Earnings Estimates

2018 EPS Consensus Estimate: ($2.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.55)($0.55)($0.55)
Q3 20181($0.58)($0.58)($0.58)
Q4 20181($0.55)($0.55)($0.55)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aimmune Therapeutics (NASDAQ AIMT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.56%
Institutional Ownership Percentage: 73.14%
Insider Trades by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics (NASDAQ AIMT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/5/2018Douglas T SheehyInsiderSell1,648$35.87$59,113.76View SEC Filing  
2/1/2018Mary M RozenmanInsiderSell6,592$35.36$233,093.12View SEC Filing  
1/24/2018Douglas T SheehyInsiderSell1,875$38.15$71,531.251,875View SEC Filing  
1/16/2018Daniel C Md AdelmanInsiderSell9,933$40.00$397,320.0026,784View SEC Filing  
1/12/2018Daniel C Md AdelmanInsiderSell26,784$40.00$1,071,360.0026,784View SEC Filing  
1/4/2018Douglas T SheehyInsiderSell1,648$37.33$61,519.841,648View SEC Filing  
1/2/2018Susan E BarrowcliffeInsiderSell75,000$37.14$2,785,500.00View SEC Filing  
12/27/2017Daniel C Md AdelmanInsiderSell3,283$40.00$131,320.003,283View SEC Filing  
12/26/2017Douglas T SheehyInsiderSell1,875$39.44$73,950.001,875View SEC Filing  
12/4/2017Douglas T SheehyInsiderSell1,906$38.66$73,685.961,906View SEC Filing  
11/30/2017Douglas T SheehyInsiderSell3,750$37.00$138,750.003,750View SEC Filing  
11/9/2017Douglas T SheehyInsiderSell1,905$33.00$62,865.001,905View SEC Filing  
10/23/2017Douglas T SheehyInsiderSell47,425$34.44$1,633,317.0034,300View SEC Filing  
10/16/2017Stephen George DillyCEOSell1,154$26.24$30,280.96View SEC Filing  
10/6/2017Stephen George DillyCEOSell4,047$26.31$106,476.57View SEC Filing  
10/5/2017Stephen George DillyCEOSell14,689$26.24$385,439.36View SEC Filing  
10/4/2017Stephen George DillyCEOSell80,110$26.23$2,101,285.30View SEC Filing  
9/25/2017Stephen George DillyCEOSell100,000$25.01$2,501,000.00View SEC Filing  
9/25/2017Susan E BarrowcliffeInsiderSell20,000$25.00$500,000.0020,000View SEC Filing  
9/7/2017Mary M RozenmanInsiderSell30,000$22.50$675,000.0030,129View SEC Filing  
9/6/2017Susan E BarrowcliffeInsiderSell18,390$22.00$404,580.003,223View SEC Filing  
7/27/2017Susan E BarrowcliffeInsiderSell500$22.00$11,000.00500View SEC Filing  
7/26/2017Stephen George DillyInsiderSell50,000$21.46$1,073,000.00View SEC Filing  
7/25/2017Susan E BarrowcliffeInsiderSell6,110$22.00$134,420.00960View SEC Filing  
7/21/2017Douglas T. SheehyInsiderSell7,460$21.66$161,583.60View SEC Filing  
7/17/2017Mary M RozenmanInsiderSell14,940$21.44$320,313.609,103View SEC Filing  
7/5/2017Mary M RozenmanInsiderSell45,060$20.85$939,501.0030,129View SEC Filing  
7/3/2017Susan E BarrowcliffeInsiderSell15,000$20.26$303,900.0015,000View SEC Filing  
6/23/2017Stephen George DillyInsiderSell49,400$20.21$998,374.00View SEC Filing  
5/12/2017Eric BjerkholtCFOBuy5,000$19.84$99,200.005,000View SEC Filing  
5/10/2017Stephen George DillyInsiderSell600$20.15$12,090.00View SEC Filing  
4/3/2017Warren L DesouzaCFOSell15,000$21.58$323,700.0035,681View SEC Filing  
3/21/2017Warren L DesouzaCFOSell10,000$22.95$229,500.0030,681View SEC Filing  
11/4/2016Mary M RozenmanInsiderSell24,096$17.60$424,089.6024,096View SEC Filing  
10/5/2016Mary M RozenmanInsiderSell25,000$16.80$420,000.0025,000View SEC Filing  
9/8/2016Mary M RozenmanInsiderSell30,000$16.80$504,000.0030,000View SEC Filing  
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aimmune Therapeutics (NASDAQ AIMT) News Headlines

Source:
DateHeadline
An Ear To The Pharma: 5 Stocks To Watch This WeekAn Ear To The Pharma: 5 Stocks To Watch This Week
www.nasdaq.com - February 18 at 8:27 AM
Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, MB, B.Ch., and Wayne ... - Business Wire (press release)Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, MB, B.Ch., and Wayne ... - Business Wire (press release)
www.businesswire.com - February 15 at 8:01 AM
Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
finance.yahoo.com - February 14 at 9:44 AM
Aimmune Therapeutics (AIMT) Earns Outperform Rating from WedbushAimmune Therapeutics (AIMT) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - February 14 at 6:00 AM
Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint CongressAimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress
finance.yahoo.com - February 12 at 9:44 AM
Aimmune Therapeutics (AIMT) Upgraded to "Hold" by BidaskClubAimmune Therapeutics (AIMT) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - February 11 at 10:16 PM
Report: Exploring Fundamental Drivers Behind Stericycle, Hemisphere Media Group, Expedia, Olin, Aimmune Therapeutics, and Waste Management — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Stericycle, Hemisphere Media Group, Expedia, Olin, Aimmune Therapeutics, and Waste Management — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - February 8 at 8:20 AM
Aimmune Therapeutics Inc (AIMT) Insider Douglas T. Sheehy Sells 1,648 SharesAimmune Therapeutics Inc (AIMT) Insider Douglas T. Sheehy Sells 1,648 Shares
www.americanbankingnews.com - February 8 at 4:02 AM
Stock Traders Purchase High Volume of Aimmune Therapeutics Call Options (AIMT)Stock Traders Purchase High Volume of Aimmune Therapeutics Call Options (AIMT)
www.americanbankingnews.com - February 8 at 1:16 AM
Wedbush Weighs in on Aimmune Therapeutics Incs FY2022 Earnings (AIMT)Wedbush Weighs in on Aimmune Therapeutics Inc's FY2022 Earnings (AIMT)
www.americanbankingnews.com - February 7 at 11:30 PM
Aimmune Therapeutics Inc (AIMT) Insider Sells $233,093.12 in StockAimmune Therapeutics Inc (AIMT) Insider Sells $233,093.12 in Stock
www.americanbankingnews.com - February 5 at 7:02 PM
Roth Capital Raises Aimmune Therapeutics (AIMT) Price Target to $75.00Roth Capital Raises Aimmune Therapeutics (AIMT) Price Target to $75.00
www.americanbankingnews.com - January 31 at 6:40 PM
Aimmune Therapeutics (AIMT) Lifted to Hold at Zacks Investment ResearchAimmune Therapeutics (AIMT) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 31 at 5:04 PM
Aimmune Therapeutics Inc (AIMT) Receives Consensus Rating of "Hold" from AnalystsAimmune Therapeutics Inc (AIMT) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 31 at 1:34 AM
Insider Selling: Aimmune Therapeutics Inc (AIMT) Insider Sells 1,875 Shares of StockInsider Selling: Aimmune Therapeutics Inc (AIMT) Insider Sells 1,875 Shares of Stock
www.americanbankingnews.com - January 26 at 9:44 PM
Aimmune Therapeutics Target of Unusually Large Options Trading (AIMT)Aimmune Therapeutics Target of Unusually Large Options Trading (AIMT)
www.americanbankingnews.com - January 19 at 3:10 AM
Insider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 9,933 Shares of StockInsider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 9,933 Shares of Stock
www.americanbankingnews.com - January 16 at 7:08 PM
Aimmune Therapeutics, Inc. (AIMT) Insider Daniel C. Md Adelman Sells 26,784 SharesAimmune Therapeutics, Inc. (AIMT) Insider Daniel C. Md Adelman Sells 26,784 Shares
www.americanbankingnews.com - January 16 at 6:38 PM
-$0.70 Earnings Per Share Expected for Aimmune Therapeutics, Inc. (AIMT) This Quarter-$0.70 Earnings Per Share Expected for Aimmune Therapeutics, Inc. (AIMT) This Quarter
www.americanbankingnews.com - January 16 at 1:08 AM
How Trading Notes Can Increase Your ProfitsHow Trading Notes Can Increase Your Profits
finance.yahoo.com - January 13 at 10:23 AM
Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut AllergyAimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
finance.yahoo.com - January 10 at 10:37 AM
Aimmune Therapeutics (AIMT) Releases 2018 Outlook; Announces Upcoming Data from Pivotal Phase 3 PALISADE ... - StreetInsider.comAimmune Therapeutics (AIMT) Releases 2018 Outlook; Announces Upcoming Data from Pivotal Phase 3 PALISADE ... - StreetInsider.com
www.streetinsider.com - January 9 at 10:26 AM
Aimmune Therapeutics (AIMT) Downgraded by Zacks Investment ResearchAimmune Therapeutics (AIMT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 8 at 9:26 PM
Aimmune Therapeutics, Inc. (AIMT) Insider Sells $61,519.84 in StockAimmune Therapeutics, Inc. (AIMT) Insider Sells $61,519.84 in Stock
www.americanbankingnews.com - January 8 at 7:28 PM
Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut AllergyAimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
finance.yahoo.com - January 8 at 10:43 AM
20 More Biopharma Catalysts Coming in 201820 More Biopharma Catalysts Coming in 2018
247wallst.com - January 6 at 10:30 AM
Aimmune Therapeutics, Inc. (AIMT) Given Average Recommendation of "Buy" by AnalystsAimmune Therapeutics, Inc. (AIMT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 6 at 1:26 AM
Cantor Fitzgerald Comments on Aimmune Therapeutics, Inc.s FY2019 Earnings (AIMT)Cantor Fitzgerald Comments on Aimmune Therapeutics, Inc.'s FY2019 Earnings (AIMT)
www.americanbankingnews.com - January 4 at 11:40 PM
Insider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 75,000 Shares of StockInsider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 75,000 Shares of Stock
www.americanbankingnews.com - January 4 at 7:02 PM
Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:47 AM
Insider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 3,283 Shares of StockInsider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 3,283 Shares of Stock
www.americanbankingnews.com - January 1 at 4:56 AM
Aimmune Therapeutics, Inc. (AIMT) Insider Sells $73,950.00 in StockAimmune Therapeutics, Inc. (AIMT) Insider Sells $73,950.00 in Stock
www.americanbankingnews.com - December 28 at 7:30 PM
Aimmune Therapeutics (AIMT) Raised to Buy at BidaskClubAimmune Therapeutics (AIMT) Raised to Buy at BidaskClub
www.americanbankingnews.com - December 27 at 9:44 PM
Aimmune Therapeutics (AIMT) Coverage Initiated by Analysts at Robert W. BairdAimmune Therapeutics (AIMT) Coverage Initiated by Analysts at Robert W. Baird
www.americanbankingnews.com - December 20 at 5:12 PM
UPDATE: Baird Starts Aimmune Therapeutics (AIMT) at Outperform; Positive Into Q18 PALISADE Data - StreetInsider.comUPDATE: Baird Starts Aimmune Therapeutics (AIMT) at Outperform; Positive Into Q18 PALISADE Data - StreetInsider.com
www.streetinsider.com - December 20 at 4:22 PM
Equities Analysts Issue Forecasts for Aimmune Therapeutics, Inc.s FY2017 Earnings (AIMT)Equities Analysts Issue Forecasts for Aimmune Therapeutics, Inc.'s FY2017 Earnings (AIMT)
www.americanbankingnews.com - December 18 at 3:28 AM
Zacks: Brokerages Anticipate Aimmune Therapeutics, Inc. (AIMT) to Announce -$0.70 EPSZacks: Brokerages Anticipate Aimmune Therapeutics, Inc. (AIMT) to Announce -$0.70 EPS
www.americanbankingnews.com - December 13 at 1:28 AM
Aimmune Therapeutics (AIMT) Receives New Coverage from Analysts at Cantor FitzgeraldAimmune Therapeutics (AIMT) Receives New Coverage from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - December 12 at 10:06 PM
Aimmune Therapeutics, Inc. (AIMT) Given Consensus Recommendation of "Hold" by AnalystsAimmune Therapeutics, Inc. (AIMT) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 12 at 1:56 AM
Aimmune Therapeutics (AIMT) Downgraded by BidaskClubAimmune Therapeutics (AIMT) Downgraded by BidaskClub
www.americanbankingnews.com - December 9 at 10:36 AM
Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14
finance.yahoo.com - December 7 at 10:58 AM
Aimmune Therapeutics (AIMT) Lowered to "Hold" at Zacks Investment ResearchAimmune Therapeutics (AIMT) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - December 6 at 7:11 PM
Douglas T. Sheehy Sells 1,906 Shares of Aimmune Therapeutics, Inc. (AIMT) StockDouglas T. Sheehy Sells 1,906 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock
www.americanbankingnews.com - December 6 at 6:21 PM
Aimmune Therapeutics (AIMT) PT Raised to $60.00Aimmune Therapeutics (AIMT) PT Raised to $60.00
www.americanbankingnews.com - December 5 at 8:58 AM
Aimmune Therapeutics, Inc. (AIMT) Insider Douglas T. Sheehy Sells 3,750 SharesAimmune Therapeutics, Inc. (AIMT) Insider Douglas T. Sheehy Sells 3,750 Shares
www.americanbankingnews.com - December 4 at 7:00 PM
Aimmune Therapeutics (AIMT) Rating Lowered to Sell at ValuEngineAimmune Therapeutics (AIMT) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 4 at 12:22 AM
Peanut Wars: Things Are Heating Up Between Aimmune Therapeutics And DBV Technologies - Seeking AlphaPeanut Wars: Things Are Heating Up Between Aimmune Therapeutics And DBV Technologies - Seeking Alpha
seekingalpha.com - December 2 at 4:19 PM
Aimmune Therapeutics (AIMT) Stock Rating Reaffirmed by WedbushAimmune Therapeutics (AIMT) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - December 1 at 4:12 PM
Aimmune Therapeutics, Inc. Fundamental Analysis : November 30, 2017Aimmune Therapeutics, Inc. Fundamental Analysis : November 30, 2017
finance.yahoo.com - November 30 at 4:22 PM
 Brokerages Anticipate Aimmune Therapeutics, Inc. (AIMT) Will Post Earnings of -$0.70 Per Share Brokerages Anticipate Aimmune Therapeutics, Inc. (AIMT) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - November 25 at 5:08 AM

SEC Filings

Aimmune Therapeutics (NASDAQ:AIMT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aimmune Therapeutics (NASDAQ:AIMT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aimmune Therapeutics (NASDAQ AIMT) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.